12/18
11:22 am
crdf
Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments [Globe and Mail, The (Toronto, Canada)]
Medium
Report
Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments [Globe and Mail, The (Toronto, Canada)]
12/13
08:31 am
crdf
Cardiff Oncology, Inc. (NASDAQ: CRDF) had its price target raised by analysts at Piper Sandler from $7.00 to $10.00. They now have an "overweight" rating on the stock.
High
Report
Cardiff Oncology, Inc. (NASDAQ: CRDF) had its price target raised by analysts at Piper Sandler from $7.00 to $10.00. They now have an "overweight" rating on the stock.
12/11
12:53 pm
crdf
Cardiff Oncology announces positive colorectal data and $40m stock oversubscription [Yahoo! Finance]
Neutral
Report
Cardiff Oncology announces positive colorectal data and $40m stock oversubscription [Yahoo! Finance]
12/11
11:22 am
crdf
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More [Yahoo! Finance]
Medium
Report
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More [Yahoo! Finance]
12/11
11:22 am
crdf
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study [Yahoo! Finance]
Medium
Report
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study [Yahoo! Finance]
12/10
10:20 am
crdf
What's Going On With Cardiff Oncology Stock On Tuesday? [Yahoo! Finance]
Low
Report
What's Going On With Cardiff Oncology Stock On Tuesday? [Yahoo! Finance]
12/10
07:20 am
crdf
Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering
High
Report
Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering
12/10
06:13 am
crdf
Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial [Yahoo! Finance]
High
Report
Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial [Yahoo! Finance]
12/10
06:00 am
crdf
Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial
High
Report
Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial
11/19
08:20 am
crdf
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC [Yahoo! Finance]
Low
Report
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC [Yahoo! Finance]
11/19
08:00 am
crdf
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC
Low
Report
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC
11/19
03:05 am
crdf
RiDYMO® Platform Drives New Breakthroughs in highly potent PLK1 Inhibitors Development [Yahoo! Finance]
Low
Report
RiDYMO® Platform Drives New Breakthroughs in highly potent PLK1 Inhibitors Development [Yahoo! Finance]
11/9
08:42 am
crdf
Cardiff Oncology Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Medium
Report
Cardiff Oncology Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/8
02:32 pm
crdf
Cardiff Oncology, Inc. (NASDAQ: CRDF) had its price target lowered by analysts at HC Wainwright from $14.00 to $13.00. They now have a "buy" rating on the stock.
Low
Report
Cardiff Oncology, Inc. (NASDAQ: CRDF) had its price target lowered by analysts at HC Wainwright from $14.00 to $13.00. They now have a "buy" rating on the stock.
11/7
04:18 pm
crdf
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update [Yahoo! Finance]
High
Report
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update [Yahoo! Finance]
11/7
04:05 pm
crdf
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update
High
Report
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update
10/30
04:30 pm
crdf
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
Low
Report
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
10/4
01:13 pm
crdf
Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market [Seeking Alpha]
Low
Report
Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market [Seeking Alpha]
10/1
05:46 pm
crdf
PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight [Yahoo! Finance]
Medium
Report
PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight [Yahoo! Finance]